Results 191 to 200 of about 163,634 (355)

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1128-1147, May 2026.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Su1629 Relation Between Serum Leptin Levels and Helicobacter pylori Infection in Patients With Dyspepsia

open access: bronze, 2012
Nafiseh Abdolahi   +4 more
openalex   +1 more source

The Symptoms and Impacts Experienced by Healthcare Professionals as Second Victims After a Safety Incident: A Scoping Review

open access: yesJournal of Advanced Nursing, Volume 82, Issue 5, Page 4538-4592, May 2026.
ABSTRACT Aim This study aimed to describe the types of psychological and physical symptoms experienced by healthcare professionals who became second victims after a patient safety incident and the impact of the incident on their social and professional lives. Design Scoping review.
Laura Jukarainen   +6 more
wiley   +1 more source

Epidemiology of Peptic Ulcer Disease: Endoscopic Results of a Systematic Investigation in Iran [PDF]

open access: yes
BACKGROUND Peptic ulcer disease is a multifactorial health problem affecting almost all populations worldwide. Large scale population-based studies are crucial to understanding its scope and specifications in various nations.
برازنده, فرهاد   +5 more
core  

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 841-855, May 2026.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin   +24 more
wiley   +1 more source

Dyspepsia

open access: yesInternational Journal of Clinical Practice, 1953
openaire   +2 more sources

Insomnia, A Comorbidity to Take Into Account in the Global Management of Patients With Irritable Bowel Syndrome?

open access: yesNeurogastroenterology &Motility, Volume 38, Issue 5, May 2026.
Insomnia in IBS is a multifactorial condition, primarily linked to psychological distress and somatic comorbidities, such as anxiety and depressive symptoms, FD and fibromyalgia rather than gastrointestinal symptoms alone. Patients with IBS and insomnia exhibit more severe overall symptoms and poorer quality of life.
Eline Albert   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy